Author: Galimedix Therapeutics, Inc.

Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies

October 1, 2026
Galimedix Therapeutics to present functional feasibility data from Phase 2 eDREAM study in geographic atrophy at 26th EURETINA Congress

September 11, 2026

Galimedix Therapeutics presents baseline data from Phase 2 eDREAM trial highlighting patient-tailored microperimetry as a sensitive and precise functional measurement in geographic atrophy studies